These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1571213)

  • 21. The influence of ifosfamide scheduling on acute nephrotoxicity in children.
    English MW; Skinner R; Pearson AD; Price L; Wyllie R; Craft AW
    Br J Cancer; 1997; 75(9):1356-9. PubMed ID: 9155058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.
    Hanly L; Rieder MJ; Huang SH; Vasylyeva TL; Shah RK; Regueira O; Koren G
    J Popul Ther Clin Pharmacol; 2013; 20(2):e132-45. PubMed ID: 23775286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
    Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
    J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
    Goren MP; Wright RK; Pratt CB; Horowitz ME; Dodge RK; Viar MJ; Kovnar EH
    Cancer Res; 1987 Mar; 47(5):1457-60. PubMed ID: 3815347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term renal function and hypertension in adult survivors of childhood sarcoma: Single center experience.
    Schiavetti A; Pedetti V; Varrasso G; Marrucci O; Celani C; Andreoli G; Bonci E
    Pediatr Hematol Oncol; 2018 Apr; 35(3):167-176. PubMed ID: 30230941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer.
    Anninga JK; Valdés Olmos RA; de Kraker J; van Tinteren H; Hoefnagel CA; van Royen EA
    Eur J Nucl Med; 1994 Jul; 21(7):658-62. PubMed ID: 7957353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrotoxicity--what do we know and what don't we know?
    Skinner R
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):128-34. PubMed ID: 21285904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic ifosfamide nephrotoxicity in children.
    Skinner R
    Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
    Skinner R
    Pediatr Nephrol; 2018 Feb; 33(2):215-225. PubMed ID: 28434047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of age upon Ifosfamide-induced nephrotoxicity.
    McCune JS; Friedman DL; Schuetze S; Blough D; Magbulos M; Hawkins DS
    Pediatr Blood Cancer; 2004 May; 42(5):427-32. PubMed ID: 15049014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ifosfamide, mesna, and nephrotoxicity in children.
    Skinner R; Sharkey IM; Pearson AD; Craft AW
    J Clin Oncol; 1993 Jan; 11(1):173-90. PubMed ID: 8418231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ifosphamide nephrotoxicity].
    Ensergueix G; Karras A
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S125-S131. PubMed ID: 29606257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and etiology of ifosfamide nephrotoxicity: report of a meeting held in Rhodes, Greece, October 3, 1991, sponsored by Asta Medica, Frankfurt, Germany.
    Stevens MC; Brandis M
    Med Pediatr Oncol; 1993; 21(9):640-4. PubMed ID: 8412996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrotoxicity from chemotherapy: prevention and management.
    Vogelzang NJ
    Oncology (Williston Park); 1991 Oct; 5(10):97-102, 105; disc. 105, 109-11. PubMed ID: 1838278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ifosfamide-induced nephrotoxicity].
    Rossi R; Rath B; Ullrich K; Ehrich JH
    Monatsschr Kinderheilkd; 1993 Jul; 141(7):594-601. PubMed ID: 8413339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refining therapeutic strategies for patients with resistant Wilm's tumor.
    Marina NM; Wilimas JA; Meyer WH; Jones DP; Douglass EC; Pratt CB
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):296-300. PubMed ID: 7978044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.
    MacLean FR; Skinner R; Hall AG; English M; Pearson AD
    Cancer Chemother Pharmacol; 1998; 41(5):413-6. PubMed ID: 9523738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.